Clinical Trials Logo

Gall Bladder Carcinoma clinical trials

View clinical trials related to Gall Bladder Carcinoma.

Filter by:

NCT ID: NCT05712356 Recruiting - Cholangiocarcinoma Clinical Trials

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

BOLSTER
Start date: August 24, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with previously untreated cholangiocarcinoma or those that have progressed after first-line treatment for cholangiocarcinoma. The main questions it aims to answer are: - is the new drug plus standard treatment safe and tolerable - is the new drug plus standard treatment more effective than standard treatment

NCT ID: NCT05320328 Recruiting - Bile Duct Neoplasms Clinical Trials

RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION

MBOP
Start date: June 10, 2021
Phase:
Study type: Observational

Endoscopic retrograde cholangio pancreatography procedure will performed as per local standard procedure.After common bile duct cannulation,cholangiography will be performed (to confirm the stricture) followed by biliary sphincterotomy. All biliary strictures(Bismuth Type I/II/III/IV) will be enrolled for the study. Patient opting for Uncovered self expandable metallic stent / Plastic stent will undergo biliary stent placement and considered under control arm Patient opting for radio frequency ablation + Uncovered SEMS/Plastic stent will undergo radio frequency ablation and biliary stent placement and considered under Study arm The RFA probe will be inserted into the bile duct alongwith the guidewire. Keeping the electrode overlapping the stricture, RFA will be performed using a power of 10W for 120 seconds. The electrode will be kept at the ablation site for an additional 1 minute to allow the RFA probe to cool before removal to prevent thermal injury of normal tissue and/or endoscope accessory channel. If the stricture is more than 3 cm, step-by-step RFA will be performed from the superior to inferior aspect. After RFA application, an uncovered SEMS/Plastic stent will be placed.

NCT ID: NCT05239169 Active, not recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Start date: May 23, 2022
Phase: Phase 2
Study type: Interventional

This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized pick-the-winner design and an option to proceed into a randomized phase 2/3 trial in order to compare the winner with the current SOC (capecitabine).

NCT ID: NCT05114369 Completed - Survival Clinical Trials

Does Timing of Completion Radical Cholecystectomy Determine the Survival in Incidental Carcinoma Gallbladder

IGBC
Start date: January 1, 2009
Phase:
Study type: Observational

Various factors determine the long term survival in this non-uniform cohort of incidental gallbladder cancer. Timing of re-intervention is suggested to play an important role in the outcome. Few centers are proponents of early surgery in order to prevent dissemination, while others have suggested an intentional delay of 3 months to filter out cases with aggressive pathology. In the present study, investigators intend to evaluate the factors affecting survival in incidental Gallbladder Cancer (IGBC) with special reference to timing of re-intervention.

NCT ID: NCT03779035 Recruiting - Cholangiocarcinoma Clinical Trials

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection

AdBTC-1
Start date: December 15, 2018
Phase: Phase 3
Study type: Interventional

This prospective, open-Label, comparative, randomized, controlled phase III trial was designed to compare the clinical performance of gemcitabine with capecitabine vs. capecitabine alone for patients with biliary tract cancer (BTC) after curative resection.

NCT ID: NCT03499782 Recruiting - Cholangiocarcinoma Clinical Trials

Precise Treatment System of Biliary Malignancies Based on Special Disease Database

Start date: May 25, 2018
Phase:
Study type: Observational

Malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. This study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use Bayesian networks and importance theory to establish a mathematical model to assess treatment strategies and prognosis accurately. At the same time, data on biliary malignant tumors newly treated by multicenters from 2018 to 2020 will be included to validate, adjust and refine the models to guide clinical individualized precise treatment.

NCT ID: NCT03473574 Completed - Cholangiocarcinoma Clinical Trials

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

IMMUCHEC
Start date: May 2, 2018
Phase: Phase 2
Study type: Interventional

To determine the efficacy in terms of objective response rate (ORR) of the combination of durvalumab and tremelimumab in addition with gemcitabine or in addition with gemcitabine and cisplatin in treatment-naïve patients with advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma (CCA).

NCT ID: NCT03027284 Completed - Solid Tumor Clinical Trials

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Start date: February 3, 2017
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.

NCT ID: NCT02631590 Completed - Cholangiocarcinoma Clinical Trials

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Start date: July 5, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.

NCT ID: NCT02170090 Active, not recruiting - Cholangiocarcinoma Clinical Trials

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

ACTICCA-1
Start date: April 2014
Phase: Phase 3
Study type: Interventional

This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. standard of care (observation alone in stage 1 and capecitabine and observation in stage 2) in patients after curative intent resection of BTC.